Sowmya Mukundan
About Sowmya Mukundan
Sowmya Mukundan is an Associate Director of Biostatistics at Ephicacy, where she has worked for ten years in various roles, including Senior Technical Lead and Manager of Biostatistics & Programming. She has previous experience as a Clinical SAS Programmer at TAKE Solutions and as an Associate SAS Programmer at Cognizant Technology Solutions.
Work at Ephicacy
Sowmya Mukundan has been with Ephicacy since 2014, holding multiple roles over the years. She currently serves as the Associate Director of Biostatistics, a position she has held since 2023. Prior to this, she worked as the Senior Technical Lead in Biostatistics and Programming, where she contributed to various projects for a decade. Additionally, she has also held the position of Manager for Biostatistics and Programming during her tenure at the company.
Previous Experience in Biostatistics
Before joining Ephicacy, Sowmya Mukundan worked at TAKE Solutions as a Clinical SAS Programmer from 2008 to 2012. This role provided her with foundational experience in clinical programming. Following her time at TAKE Solutions, she worked at Cognizant Technology Solutions as an Associate SAS Programmer from 2013 to 2014, further enhancing her skills in biostatistics and programming.
Education and Expertise
Sowmya Mukundan possesses a strong background in biostatistics and programming, which is reflected in her career trajectory. Her expertise includes clinical programming and statistical analysis, which she has applied in various roles throughout her career. Her educational qualifications support her professional roles, although specific details about her education are not provided.
Career Timeline
Sowmya Mukundan's career in biostatistics spans over 15 years. She began her professional journey in 2008 at TAKE Solutions and transitioned to Cognizant Technology Solutions in 2013. In 2014, she joined Ephicacy, where she has progressed through several roles, culminating in her current position as Associate Director of Biostatistics in 2023.